Malignant Peritoneal and Retroperitoneal Neoplasm

Malignant Peritoneal and Retroperitoneal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

631 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 163
Recruiting: 76
Ph III recruiting: 8
Growth YoY: −39.1%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (92)

clinicaltrialsPublishedShowing 51–83 of 83 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02673333	Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma	active not recruiting	Phase 2	39	Memorial Sloan Kettering Cancer CenterOTHER	1	Apr 6, 2026	clinicaltrials
NCT03017131	Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	Phase 1	9	Roswell Park Cancer InstituteOTHER	1	Apr 6, 2026